Get startedLog in
    Picture of Praxis Precision Medicines logo

    PRAX — Praxis Precision Medicines News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapMomentum Trap
    All News

    Brief: Praxis Precision Medicines Announces Positive Results From Phase 3 Studies

    Picture of Praxis Precision Medicines logoPraxis Precision Medicines
    16/10/2025 12:39
    Oct 16 (Reuters) - Praxis Precision Medicines Inc PRAX.O:

PRAXIS PRECISION MEDICINES ANNOUNCES POSITIVE TOPLINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF ULIXACALTAMIDE HCL IN THE ESSENTIAL3 PROGRAM FOR ESSENTIAL TREMOR

PRAXIS PRECISION MEDICINES INC - ULIXACALTAMIDE WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

PRAXIS PRECISION MEDICINES INC - SUBMITS PRE-NDA MEETING REQUEST TO FDA

PRAXIS PRECISION MEDICINES INC - STUDY 2 MET ITS PRE-SPECIFIED PRIMARY ENDPOINT, SHOWS SUPERIOR MAINTENANCE WITH ULIXACALTAMIDE

PRAXIS PRECISION MEDICINES INC -  FIRST KEY SECONDARY ENDPOINT IN STUDY 2 DEMONSTRATED SUPERIOR EFFECT IN ULIXACALTAMIDE TREATED PATIENTS VERSUS PLACEBO

PRAXIS PRECISION MEDICINES INC - ALL KEY SECONDARY ENDPOINTS IN STUDY 1 WERE ALSO STATISTICALLY SIGNIFICANT

Source text: ID:nGNX90ZjPb

Further company coverage: PRAX.O

 ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Praxis Precision Medicines

    See all news